Clinical Trials Logo

Relapsed Pediatric ALL clinical trials

View clinical trials related to Relapsed Pediatric ALL.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04888468 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Start date: November 5, 2019
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of pCAR-19B in patients with relapsed or refractory B-ALL, and to obtain the maximum tolerated dose of pCAR-19B and phase II Recommended dose.

NCT ID: NCT04562792 Completed - Clinical trials for Refractory Acute Myeloid Leukemia

Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia

Start date: May 8, 2020
Phase: Phase 2
Study type: Interventional

In this pilot study, eligible pediatric patients will be treated with 5 consecutive days of low dose daunorubicin. All patients who receive low dose daunorubicin will be evaluated daily for potential toxicity during those 5 days. Once the patient has received 5 doses of daunorubicin, subsequent therapy will be at the discretion of the primary oncology team.